Categories: News

Leveljump Healthcare Corp. Enters into Private Placement for Proceeds of $100,000

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Toronto, Ontario–(Newsfile Corp. – July 23, 2021) – Leveljump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) (“Leveljump” or “the “Company“) wishes to announce that it has entered into a private placement agreement with a corporate subscriber to issue 250,000 common shares at a price of $0.40 per share for gross proceeds of $100,000. There are no finder’s fees payable in connection with this placement. The proceeds will be allocated by the Company primarily towards the creation of additional online content in various social media platforms. Such content shall be proprietary to Leveljump.

Closing of this placement is subject to the consent of the TSX Venture Exchange.

All securities issued will be subject to a hold period of four months and one day pursuant to applicable securities laws.

Additionally the Company issued 2,000 shares as settlement for $800 of debt to two employees on June 9, 2021.

About Leveljump Healthcare

Leveljump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging compajavascript:void(0);ny and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business plans and the outlook of the Company’s industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91107

Staff

Recent Posts

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation for Clinical and Commercial Success | DelveInsight

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized…

49 minutes ago

Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication…

49 minutes ago

OpenLight Achieves Successful Completion of Telcordia GR-468 Qualification for Silicon Photonics Components

Milestone in optoelectronics provides significant assurance in the design and manufacturing process of advanced optoelectronic…

49 minutes ago

Earnest Analytics launches AI-powered data summaries in its online platform, Dash

NEW YORK, March 24, 2025 /PRNewswire/ -- Earnest Analytics, the leading data analytics firm for…

49 minutes ago

A New Milestone in Electronic Fetal Monitoring: FDA 510(k) Clearance Granted for Dawes-Redman CTG Analysis™

ADDISON, Ill., March 24, 2025 /PRNewswire/ -- Huntleigh Healthcare is proud to announce that the…

49 minutes ago

Techcyte Unveils Fusion, the First Unified Anatomic and Clinical Digital Pathology Platform

OREM, Utah--(BUSINESS WIRE)--#AIinPathology--Techcyte, a leader in AI-powered digital pathology, announced the launch of Fusion, the…

7 hours ago